



Press release F4 Pharma – Vienna / November 10, 2014

## **F4 Pharma's developmental drug FX06 successful in treating vascular leak in Ebola**

### **First highly encouraging results in treating an Ebola infected patient in Frankfurt with FX06**

The University Hospital in Frankfurt reported the successful treatment of an Ebola patient medically evacuated from Sierra Leon. The compound FX06, developed in Austria, was used by experts of the University Hospital in Frankfurt under compassionate use after approval by the ethic committee. FX06 could substantially contribute to the recovery of the patient. The substance had been developed by a scientist at the Vienna General Hospital (AKH) and has the potential to decisively influence the outcome of an Ebola infection.

“Originally we wanted to focus on another indication and were in the course of raising funds when we realized that all our preclinical and clinical data of FX06 are addressing principally one of the most dramatic disease patterns of Ebola, the so-called ‘vascular leak’. FX06 is sealing the walls of the blood vessels which become leaky during the disease course with the consequence of severe and irreparable damage of vital organs like kidney, liver and lung.” This can be life saving” declares Mr. Thomas Steiner. The Viennese entrepreneur is CEO of the company MChE F4-Pharma.

“We had already been in contact with the WHO and other international organizations when we received the request from Frankfurt. Fortunately the manufacturer of our substance, Bachem, was able to deliver FX06 immediately and in an un-bureaucratic procedure to Frankfurt.”

“We actually created the prerequisites for further compassionate use in Europe and our drug is stored centrally at the University of Frankfurt. Now the challenge is to overcome any arising further regulatory documentations before we can start a clinical trial in West Africa” states the biotechnical expert Dr. Petra Wülfroth of F4-Pharma.

The cooperation with the team at the University Hospital in Frankfurt, headed by Prof. Dr. Kai Zacharowski, is a cardinal point to facilitate the use of FX06 in specialized centers in Europe and also in West Africa at the earliest convenience. The scientific research performed in intensive care units in European and US are prerequisites to understand the course of this striking epidemic.

“As a matter of fact MChE F4-Pharma is in urgent need of support and is looking for further funds. We hope to be able to count on investors of the public and private sector in order to have FX06 ready as soon as possible against Ebola world-wide” concludes Mr. Steiner. The manufacturer of FX06, Bachem, already donated material in the value of several 100.000 €.

*Vienna, November 10, 2014*